The National Environmental Policy Act (NEPA) handicaps energy developers and subjects them to a stifling bureaucratic process that is preventing them from building the energy infrastructure America needs to get and stay ahead of its geopolitical rivals.
🧵
NEPA means review.
If you want to build something, the environmental impact has to be assessed. You need an environmental impact statement, and it can take a long time to deal with those.
So long, in fact, that many projects just shut down.
These projects are not one-offs either.
In fact, most solar and pipeline projects get hit by environmental impact statements, and large portions of them are canceled after putting up with the delays.
Often when we talk about the government impeding progress, we talk about invisible graveyards.
For example, in the 1980s, it was alleged that the FDA created an invisible graveyard of gay men who couldn't get sufficient medical treatment for HIV as a result of agency decisions.
With NEPA, it's harder to see what the regulations cause us to miss out on because the graves aren't usually so literal.
But we have something very close: wildfires.
I'm sure some of you will remember when the sky over San Francisco turned an eerie red.
Destructive wildfires are unfortunately common in the U.S., but they don't have to be
Sadly, when the Forest Service applies to treat more forest to prevent wildfires, they have to undergo NEPA review, delaying their ability to do their jobs.
Result? Flammable, overgrown woods.
The irony of the "National Environmental Policy Act" is that it is killing the environment.
Entrepreneurs and the government alike want to do things to make the U.S. a greener, safer, and less polluted place, but NEPA has made that process arduous and often impossible.
Like the Jones Act, NEPA must be fixed.
All of this comes from @AidanRMackenzie's new piece on NEPA and the need for reform.
The state of Louisiana has managed to reduce its Hepatitis C death rate by nearly a sixth in just a few years through a clever public health program🧵
Louisiana's success has to do with the recent development of a miraculous change in how Hepatitis C (HCV) is treated.
Prior to 2013, HCV was primarily treated with drugs like interferon and ribavirin, but the drugs were not consistently effective at clearing the virus.
But then the FDA approved the first direct-acting antiviral (DAA), sofosbuvir, a liver-targeting NS5B protein inhibitor that, combined with another protein inhibitor (velpatasvir), is effective in treating 95-99% of HCV patients.
We finally have large-scale cross-sectional functional connectome scans for people aged young and old.
The finding that was most interesting to me in all this is that the brain's functional connectome seems to grow until about age 38, whereafter it starts shrinking.
Ignore the tails, because they're impacted by variance.
But speaking of, it seems that the global variance in the form of the connectome also grows until about age 28, whereafter it starts becoming less variable.
This is really interesting new data, and I'm happy to see it published.
Hopefully in a few decades, we'll have longitudinal data to see if what we see in the cross-section holds up within individuals, too!
Pirenne's thesis holds that Antiquity—the period when economic activity concentrated in the Mediterranean—ended because the rise of Islam destroyed the flow of trade across it.
The decline in trade that resulted from differences in faith had profound consequences for the economic geography of Europe.
Byzantine economic activity depended on trade, and it collapsed, whereas the Frankish economy, which was never trade-dependent, transformed.
The Byzantines' minting stalled and the Arabs' and Franks' increased (perhaps partly because they were cut off from one another!), providing each of their states with divergent trends in seignorage revenues and a widening gulf in the ability to fund the government.
At every age, the incidence of dementia is down. As a society, people are no longer suffering dementia nearly as often!
The world over, child mortality is way down. It's unusual for parents to experience the death of a child these days, where even a century ago, it was the global norm.
Each year, novel gene therapies are approved.
The number of gene therapies in the pipeline is also rapidly increasing. There is tons of progress to be made here, and the main issue is regulatory.
We have lots of low-hanging fruit in curing disease!